BRIEF—Phase III study finds adjuvant Epidiolex helps reduce seizures

UK-based cannabinoid specialist GW Pharmaceuticals has published results from its study into lead candidate Epidiolex (cannabidiol) in patients with Lennox-Gastaut syndrome (LGS).

The firm’s US subsidiary Greenwich Biosciences says the therapy showed “significantly reduced monthly drop seizure frequency compared to placebo in highly treatment-resistant patients,” when added to existing treatment.

Late last year the US FDA gave priority status to the firm’s new drug application, with a decision expected by the end of June. A decision on the firm’s EU submission is expected early next year.

The firm is studying Epidiolex for the treatment of a number of rare, severe pediatric-onset epilepsy disorders.

The results were published in The Lancet.